Stevanato Group reported Q2 2026 revenue of €302 million, an 8% year-over-year increase, driven by a 9% rise in Biopharmaceutical and Diagnostic Solutions (BDS) that offset a 2% decline in Engineering. The company completed the divestiture of Balda C. Brewer, recording €12.2 million in one-time expenses. Adjusted EBITDA grew 21% to €78.7 million with a 26% margin, while adjusted diluted EPS rose to €0.14. Management updated full-year guidance, expecting revenue between €1.26 billion and €1.28 billion and adjusted EBITDA of €335 million to €345.2 million. The firm operates in the pharmaceutical packaging and drug delivery systems industry.
